RxDoctor Payments Data

Walter Few, MD

Interventional Cardiology · Chattanooga, TNNPI 1699749010

Payments from drug & device makers

$19,380in general payments, 2019–2025

Across 770 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$2K
  • Boston Scientific$1K
  • Abiomed$1K
  • Johnson & Johnson$1K
  • Inari Medical, Inc.$954
  • plus $9K from 41 others

What the payments were for

  • Travel & lodging$2942%
  • Food & beverage$19,07398%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,380 in reported general payments places this provider in the 70th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$106,726
Medicare patients
477
Services billed
1,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$123,120
XareltoRivaroxaban66$84,971
EntrestoSacubitril/Valsartan53$65,041
FarxigaDapagliflozin Propanediol40$46,189
Repatha SureclickEvolocumab35$26,148
BrilintaTicagrelor18$17,139
Ranolazine ErRanolazine29$4,999
Metoprolol Succinate228$3,617
Atorvastatin Calcium200$2,746
Losartan Potassium163$1,761
Carvedilol217$1,671
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$1,669
Rosuvastatin Calcium145$1,604
ClopidogrelClopidogrel Bisulfate141$1,559
Nebivolol Hcl16$1,530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$596$123,120136 claims
Johnson & JohnsonXarelto$1,014$84,97166 claims
NovartisEntresto$934$65,04153 claims
AstraZenecaFarxiga, Brilinta$690$63,32858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →